Because compound 2 was also previously shown to inhibit CYP17, results from the present study suggest it may be possible to design dual AKR1C3/CYP17 inhibitors for potential use in the treatment of advanced prostate cancer based on a steroid scaffold. Here, CYP17A1 is linked to prostate cancer.